A Study of X-VRD Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities
Status:
Recruiting
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label study to evaluate the efficacy and safety of XVRD(Selinexor,
Bortezomib, Lenalidomide and Dexamethasone) regimen combined with CART-ASCT-CART2 in Chinese
patients with newly diagnosed multiple myeloma with p53 gene abnormalities.